Unlock the secrets of executive presence in pharma to inspire confidence, influence decisions, and elevate your leadership ...

Global leader in mother and childcare, Philips Avent, announced a partnership with March of Dimes to establish the modern-day ...

According to the terms of the agreement, Sanofi will acquire London-based Vicebio’s entire share capital for an upfront ...

A timeline of key developments surrounding Sarepta Therapeutics' Duchenne muscular dystrophy drug Elevidys, and the potential ...

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, explains how the approval of Emrelis is accelerating investor interest, validating biomarker-driven ADCs, and shaping distinct strategic ...

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, highlights Emrelis’ potential to broaden its clinical impact ...

Biotech veteran and Stanford physician-scientist brings 30 years of translational research and regulatory experience to ...

Copycats and false advertisements are also to blame for the increased threats. Stemming from social media testimonials all ...

A special live broadcast of award-winning star and CEO’s conversation will focus on advancements and regulations on ALS ...

With reports that FDA’s AI Elsa is “confidently hallucinating” studies that don’t exist, the use of AI to streamline drug review and speed up approval is not here yet.

The FDA’s complete response letter cited concerns that the Phase I/II IGNYTE (CT03767348) trial in advanced melanoma was not ...

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, explains how the approval of Embrelis marks a pivotal moment ...